Cited by 161Parkinson's Disease Mechanisms and TreatmentsAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Anxiety in Parkinson's disease: identification and management

Open access

Chen, Jack J., Marsh, Laura·2014·Therapeutic Advances in Neurological Disorders

DOI 10.1177/1756285613495723PMC PMC3886380

Open this paper in CoChat — free account

Abstract

Anxiety disturbances are recognized as common psychiatric comorbidities in Parkinson’s disease (PD) and contribute to significant impairments in areas of cognitive, functional, motor and social performance. Anxiety in PD results in reduced quality of life, higher levels of care dependency and increased caregiver burden. Surprisingly, there is a paucity of treatment data. In one randomized, controlled study, bromazepam was found to be effective for anxiety in PD. However, usage of benzodiazepines in the PD population is limited by potential risk of confusion and falls. There are no controlled studies of selective serotonin reuptake inhibitors (SSRIs) for anxiety in PD. However, results from uncontrolled studies suggest that SSRIs are effective for anxiety in PD, although in these studies anxiety outcomes were secondary. This review underscores that, given the high prevalence of anxiety disturbances in PD, there is a significant paucity of treatment data for this population. Additional studies are warranted. In the meantime, clinicians should rely on empiric assessments of known risks and putative benefits to guide treatment decisions. Cognitive and behavioral therapies (with or without pharmacotherapy) have demonstrated efficacy and warrant consideration. When feasible, a targeted and individualized multimodal approach utilizing psychotherapeutic interventions along with pharmacologic therapies should be considered.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1177/1756285613495723

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
An inventory for measuring clinical anxiety: Psychometric properties.
Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.56.6.893 · Cited by 14,407
An Essay on the Shaking Palsy
Parkinson, J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.223 · Cited by 2,856
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system
Rémy, P., Doder, M., Lees, A. J., Turjanski, N., & Brooks, D. J. (2005) · Brain · doi:10.1093/brain/awh445 · Cited by 1,090
Drug Facts and Comparisons 1991.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-823_1 · Cited by 776
Non-recognition of depression and other non-motor symptoms in Parkinson's disease
Shulman, L. M., Taback, R. L., Rabinstein, A. A., & Weiner, W. J. (2002) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(01)00015-3 · Cited by 695
Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling
Witjas, T., Kaphan, E., Azulay, J. P., Blin, O., Ceccaldi, M., Pouget, J., Poncet, M., & Chérif, A. A. (2002) · Neurology · doi:10.1212/wnl.59.3.408 · Cited by 642
Factors impacting on quality of life in Parkinson's disease: Results from an international survey
The Global Parkinson's Disease Survey (GPDS) Steering Committee (2002) · Movement Disorders · doi:10.1002/mds.10010 · Cited by 524
What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?
Gallagher, D. A., Lees, A. J., & Schrag, A. E. (2010) · Movement Disorders · doi:10.1002/mds.23394 · Cited by 506

Show all 69 references

Research works printed but not linked: 6

Black K., 2000, J Psychiatry Neurosci, 25, 255
Casacchia M., 1975, Riv Neurol, 45, 326
Hanna K., 2012, Parkinsons Dis, 2012, 640707
Kano O., 2011, Parkinsons Dis, 2011, 143547
Richard I., 2004, Cogn Behav Neurol, 17, 201
Shulman L., 1996, Mov Disord, 11, 12

Sorted by citations

Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 557
Health-Related Quality of Life in patients with Parkinson's disease—A systematic review based on the ICF model
van Uem, J. M. T., Marinus, J., Canning, C. G., van Lummel, R. C., Dodel, R. C., Liepelt‐Scarfone, I., Berg, D., Morris, M. E., & Maetzler, W. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.11.014 · Cited by 218
The T herapeutic P otential of E xercise to I mprove M ood, C ognition, and S l eep in P arkinson's D isease
Reynolds, G., Otto, M. W., Ellis, T. D., & Cronin‐Golomb, A. (2015) · Movement Disorders · doi:10.1002/mds.26484 · Cited by 144
The clinical spectrum of anxiety in Parkinson's disease
Dissanayaka, N. N. N. W., White, E., O'Sullivan, J. D., Marsh, R., Pachana, N. A., & Byrne, G. J. (2014) · Movement Disorders · doi:10.1002/mds.25937 · Cited by 124
Psychiatric Manifestation in Patients with Parkinson's Disease
Han, J. W., Ahn, Y. D., Kim, W.-S., Shin, C. M., Jeong, S. J., Song, Y. S., Bae, Y. J., & Kim, J.-M. (2018) · Journal of Korean Medical Science · doi:10.3346/jkms.2018.33.e300 · Cited by 127
Dysfunctional Limbic Circuitry Underlying Freezing of Gait in Parkinson’s Disease
Gilat, M., Martens, K. A. E., Miranda-Domínguez, Ó., Arpan, I., Shine, J. M., Mancini, M., Fair, D. A., Lewis, S. J. G., & Horak, F. B. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.044 · Cited by 123
Parkinson’s disease: a review of non-motor symptoms
Rana, A. Q., Ahmed, U. S., Chaudry, Z. M., & Vasan, S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1038244 · Cited by 122
The effect of resistance training on the anxiety symptoms and quality of life in elderly people with Parkinson's disease: a randomized controlled trial
Ferreira, R. M., Alves, W. M. G. D. C., de Lima, T. A., Alves, T. G. G., Filho, P. A. M. A., Pimentel, C. P., de Sousa, E. C., & Cortinhas‐Alves, E. A. (2018) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20180071 · Cited by 130
Neurodegenerative disorders and gut-brain interactions
Singh, A., Dawson, T. M., & Kulkarni, S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143775 · Cited by 104
Remote delivery of psychological interventions for Parkinson's disease.
Swalwell, C., Pachana, N. A., & Dissanayaka, N. N. (2018) · International Psychogeriatrics · doi:10.1017/s1041610218000340 · Cited by 87
“, 2013), and concerns regarding unfavorable side effects, including exacerbation of motor problems in patients with complex medication regimes, have been noted (Rabinstein and Shulman, 2000; Veazey et al., 2005; Chen and Marsh, 2014).”
Background
Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinson’s Disease
Green, H. F., Khosousi, S., & Svenningsson, P. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191699 · Cited by 84
Melatoninergic System in Parkinson’s Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms
Mack, J. M., Schamne, M. G., Sampaio, T. B., Pértile, R. A. N., Fernandes, P. A. C. M., Markus, R. P., & Prediger, R. D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3472032 · Cited by 81
Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis
Landau, S., Harris, V., Burn, D. J., Hindle, J. V., Hurt, C. S., Samuel, M., Wilson, K. C., & Brown, R. G. (2015) · Psychological Medicine · doi:10.1017/s0033291715002196 · Cited by 78
Anxiety: An ignored aspect of Parkinson's disease lacking attention.
Khatri, D., Choudhary, M., Sood, A., & Singh, S. B. (2020) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2020.110776 · Cited by 65
The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
Chen, S., Chan, P., Sun, S., Chen, H., Zhang, B., Le, W., Liu, C., Peng, G., Tang, B., Wang, L., et al. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0059-z · Cited by 77
Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson’s Disease
Murueta‐Goyena, A., Andikoetxea, A., Gómez‐Esteban, J. C., & Gabilondo, I. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01294 · Cited by 72
Pathophysiology of non-motor signs in Parkinson’s disease: some recent updating with brief presentation
Radad, K., Moldzio, R., Krewenka, C., Kranner, B., & Rausch, W. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00036 · Cited by 68
Disease-specific anxiety symptomatology in Parkinson's disease
Dissanayaka, N. N., O’Sullivan, J. D., Pachana, N. A., Marsh, R., Silburn, P. A., White, E., Torbey, E., Mellick, G. D., Copland, D. A., & Byrne, G. J. (2016) · International Psychogeriatrics · doi:10.1017/s1041610215002410 · Cited by 59
Cognitive-Behavioral Therapy for Anxiety in Parkinson’s Disease
Reynolds, G. O., Saint-Hilaire, M., Thomas, C. A., Barlow, D. H., & Cronin-Golomb, A. (2020) · Behavior Modification · doi:10.1177/0145445519838828 · Cited by 59
A Stage-Based Approach to Therapy in Parkinson’s Disease
Carrarini, C., Russo, M., Dono, F., Pietro, M. D., Rispoli, M. G., Stefano, V. D., Ferri, L., Barbone, F., Vitale, M., Thomas, A., et al. (2019) · Biomolecules · doi:10.3390/biom9080388 · Cited by 58
Cognitive Behavior Therapy for Anxiety in Parkinson’s Disease: Outcomes for Patients and Caregivers
Dissanayaka, N. N., Pye, D., Mitchell, L. K., Byrne, G. J., O’Sullivan, J. D., Marsh, R., & Pachana, N. A. (2016) · Clinical Gerontologist · doi:10.1080/07317115.2016.1240131 · Cited by 58
Cognitive behavioural interventions for depression in chronic neurological conditions: A systematic review
Fernie, B. A., Kollmann, J., & Brown, R. G. (2015) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2015.02.012 · Cited by 51
Anxiety and Depression in Parkinson’s Disease
Djamshidian, A., & Friedman, J. H. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0285-6 · Cited by 47
Relationships among Depression, Anxiety, Sleep, and Quality of Life in Patients with Parkinson’s Disease in Taiwan
Fan, J., Chang, B., & Wu, Y. (2016) · Parkinson s Disease · doi:10.1155/2016/4040185 · Cited by 44
Demoralization and Quality of Life of Patients with Parkinson Disease
Zhu, B.-H., Kohn, R., Patel, A. S., Koo, B. B., Louis, E., & de Figueiredo, J. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000514270 · Cited by 41
Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer’s and Parkinson’s disease
Reich, N., & Hölscher, C. (2024) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2024.101122 · Cited by 43
Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease
Diederich, N. J., Goldman, J. G., Stebbins, G. T., & Goetz, C. G. (2015) · Movement Disorders · doi:10.1002/mds.26460 · Cited by 41
Anxiety, depression, and quality of life in Parkinson’s disease: the implications of multidisciplinary treatment
Buono, V. L., Palmeri, R., Salvo, S. D., Berenati, M., Greco, A., Ciurleo, R., Sorbera, C., Cimino, V., Corallo, F., Bramanti, P., et al. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.293151 · Cited by 41
Characteristics and Treatment of Anxiety Disorders in Parkinson's Disease
Dissanayaka, N. N., White, E., O’Sullivan, J. D., Marsh, R., Silburn, P. A., Copland, D. A., Mellick, G. D., & Byrne, G. J. (2015) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12157 · Cited by 39
Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations
Fernandes, M., Pierantozzi, M., Stefani, A., Cattaneo, C., Bonizzoni, E., Cerroni, R., Mercuri, N. B., & Liguori, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.678373 · Cited by 38
Detecting anxiety in individuals with Parkinson disease
Mele, B., Holroyd-Leduc, J. M., Smith, E. E., Pringsheim, T. M., Ismail, Z., & Goodarzi, Z. (2017) · Neurology · doi:10.1212/wnl.0000000000004771 · Cited by 36
Impact of a keto diet on symptoms of Parkinson's disease, biomarkers, depression, anxiety and quality of life: a longitudinal study
Tidman, M. M., White, D. R., & White, T. A. (2024) · Neurodegenerative Disease Management · doi:10.1080/17582024.2024.2352394 · Cited by 34
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies
Lai, T. T., Gericke, B., Feja, M., Conoscenti, M. A., Zelikowsky, M., & Richter, F. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00547-4 · Cited by 34
Emotion in action: When emotions meet motor circuits
Braine, A., & Georges, F. E. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105475 · Cited by 37
Insomnia in Parkinson’s Disease: Causes, Consequences, and Therapeutic Approaches
Duan, X., Liu, H., Hu, X., Yu, Q., Kuang, G., Liu, L., Zhang, S., Wang, X., Li, J., Yu, D., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04400-4 · Cited by 38
Perceptions of people living with Parkinson's disease: a qualitative study in Iran
Soleimani, M. A., Bastani, F., Negarandeh, R., & Greysen, R. (2016) · British Journal of Community Nursing · doi:10.12968/bjcn.2016.21.4.188 · Cited by 31
Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease
Torres, E. R. S., Stanojlović, M., Zelikowsky, M., Bonsberger, J., Hean, S., Mulligan, C. K., Baldauf, L., Fleming, S. M., Masliah, E., Chesselet, M., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105478 · Cited by 28
The Possible Role of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 on Locomotor Activity and Oxidative Stress in a Rotenone‐Induced Zebrafish Model of Parkinson’s Disease
Ilie, O., Paduraru, E., Robea, M. A., Balmuș, I.-M., Jijie, R., Nicoară, M., Ciobica, A. S., Nita, I.-B., Dobrin, R., & Doroftei, B. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9629102 · Cited by 27
Commentary: Evaluation of Models of Parkinson's Disease
Leal, P. C., Lins, L. C. R. F., de Gois, A. M., Marchioro, M., & dos Santos, J. R. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00283 · Cited by 26
Management of anxiety and motor symptoms in Parkinson’s disease
Coakeley, S., Martens, K. A. E., & Almeida, Q. J. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.936388 · Cited by 25
The impact of motor symptoms on self-reported anxiety in Parkinson's disease
Salazar, R. D., Le, A. M., Neargarder, S. A., & Cronin‐Golomb, A. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.01.011 · Cited by 25
Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.
DeMaagd, G. A., & Philip, A. (2015) · PubMed Central · Cited by 23
Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson’s disease or essential tremor who have undergone deep brain stimulation
Achey, R., Yamamoto, E. A., Sexton, D., Hammer, C. L., Lee, B. S., Butler, R. S., Thompson, N. R., Nagel, S. J., Machado, A. G., & Lobel, D. A. (2018) · Journal of neurosurgery · doi:10.3171/2017.8.jns1733 · Cited by 23
Long-Term Treatment with Fluvoxamine Decreases Nonmotor Symptoms and Dopamine Depletion in a Postnatal Stress Rat Model of Parkinson’s Disease
Dallé, E., Daniels, W. M. U., & Mabandla, M. V. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1941480 · Cited by 20
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s Disease
Antipova, V., Holzmann, C., Hawlitschka, A., Witt, M., & Wree, A. (2021) · Toxins · doi:10.3390/toxins13070505 · Cited by 20
Sustained chemogenetic activation of locus coeruleus norepinephrine neurons promotes dopaminergic neuron survival in synucleinopathy
Jovanović, P., Wang, Y., Vit, J., Novinbakht, E., Morones, N., Hogg, E. J., Tagliati, M., & Riera, C. E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263074 · Cited by 22
A Systematic Review of Psychotherapy Approaches for Anxiety in Parkinson's Disease.
Roper, A., Pacas Fronza, G., Dobkin, R. D., Beaudreau, S. A., Mitchell, L. K., Pachana, N. A., Thangavelu, K., & Dissanayaka, N. N. (2024) · Clinical Gerontologist · doi:10.1080/07317115.2022.2074814 · Cited by 19
Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism
Leal, P. C., Bispo, J. M. M., Lins, L. C. R. F., Souza, M. F., de Gois, A. M., Moore, C., Marchioro, M., Ribeiro, A. M., Silva, R. H., Meshul, C. K., et al. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.01.009 · Cited by 19
Nonpharmacologic Interventions for the Self-Management of Anxiety in Parkinson’s Disease: A Comprehensive Review
Chandler, S. K., Robins, J. L. W., & Kinser, P. A. (2019) · Behavioural Neurology · doi:10.1155/2019/8459579 · Cited by 19
Activities of daily living as a longitudinal moderator of the effect of autonomic dysfunction on anxiety and depression of Parkinson's patients
Cui, J., Qin, Y., Tian, Y., Ge, X., Han, H., Yang, Z., & Yu, H. (2021) · Brain and Behavior · doi:10.1002/brb3.2297 · Cited by 19
Management of Psychiatric Disorders in Patients with Parkinson’s Diseases
Tripathi, A., Gupta, P. K., & Bansal, T. (2022) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_29_22 · Cited by 18
The Relationship Between Autonomic Dysfunction of the Gastrointestinal Tract and Emotional Distress in Patients With Systemic Sclerosis
DiRenzo, D., Russell, J. W., Bingham, C. O., & McMahan, Z. H. (2019) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001144 · Cited by 18
Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson’s Disease
Elefante, C., Brancati, G. E., Bacciardi, S., Mazzucchi, S., Prete, E. D., Palermo, G., Frosini, D., Bonuccelli, U., Ceravolo, R., Lattanzi, L., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112302 · Cited by 18
Multidimensional mechanisms of anxiety and depression in Parkinson’s disease: Integrating neuroimaging, neurocircuits, and molecular pathways
Zhao, J., Jia, H., Ma, P., Zhu, D. Y., & Fang, Y. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107717 · Cited by 20
Odorants: a tool to provide nonpharmacological intervention to reduce anxiety during normal and pathological aging
Ballanger, B., Bath, K. G., & Mandairon, N. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.06.007 · Cited by 23
REM sleep deprivation promotes a dopaminergic influence in the striatal MT2 anxiolytic-like effects
Noseda, A. C. D., Targa, A., Rodrigues, L. S., Aurich, M. F., & Lima, M. M. S. (2015) · Sleep Science · doi:10.1016/j.slsci.2015.10.002 · Cited by 17
Motion and emotion: anxiety–axial connections in Parkinson’s disease
Šumec, R., Rektorová, I., Jech, R., Menšíková, K., Roth, J., Růžička, E., Sochorová, D., Dušek, L., Kaňovský, P., Rektor, I., et al. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1652-0 · Cited by 16
Comprehensive Review on Parkinson's Disease: Insights into Prevalence, Pathophysiology, Diagnosis, and Multifaceted Treatment Approaches
Kumar, L., Malhotra, M., SINGH, A. P., & Singh, A. P. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i6.6637 · Cited by 14
Leveraging animal models to understand non-motor symptoms of Parkinson's disease
Wichmann, T., Nelson, A., Torres, E. R. S., Svenningsson, P., & Marongiu, R. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106848 · Cited by 14
Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease
Sauerbier, A., Herberg, J., Stopic, V., Loehrer, P. A., Ashkan, K., Rizos, A., Jost, S. T., Petry‐Schmelzer, J. N., Gronostay, A., Schneider, C. A., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00701-6 · Cited by 13
Injectable Hierarchical Bioactive Hydrogels with Fibroblast Growth Factor 21/Edaravone/Caffeic Acid Asynchronous Delivery for Treating Parkinson's Disease
Xu, J., Dai, P., Zhang, C., Dong, N., Li, C., Tang, C., Jin, Z., Lin, S., Ye, L., Sun, T., et al. (2024) · Advanced Science · doi:10.1002/advs.202412020 · Cited by 14
A network-based systems genetics framework identifies pathobiology and drug repurposing in Parkinson’s disease
Dou, L., Xu, Z., Xu, J., Zang, C., Su, C., Pieper, A. A., Leverenz, J. B., Wang, F., Zhu, X., Cummings, J. L., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00870-y · Cited by 21
The impact of traumatic brain injury on cognitive and neuropsychiatric symptoms of Parkinson’s disease
Joyce, J. M., Monchi, O., Ismail, Z., Kibreab, M., Cheetham, J., Kathol, I., Sarna, J. R., Martino, D., & Debert, C. T. (2019) · International Review of Psychiatry · doi:10.1080/09540261.2019.1656177 · Cited by 13
Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics
Butala, A., Shepard, M. D., & Pontone, G. M. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00007-1 · Cited by 13
Understanding the Influence of Pain and Fatigue On Physical performance, Fear of Falling and Falls in People With Parkinson’s Disease: A Pilot Study
Khalil, H. W., Alissa, N., Al‐Sharman, A., E’Leimat, I., Qawasmeh, M. A., & El‐Salem, K. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0053 · Cited by 13
Depression and Anxiety Management in Parkinson Disease
Ho, H., Jose, I., Cheesman, M., Garrison, C., Bishop, K., Taber, S., Witt, J. L., & Sin, M. (2021) · Journal of Neuroscience Nursing · doi:10.1097/jnn.0000000000000596 · Cited by 13
The Common Denominators of Parkinson’s Disease Pathogenesis and Methamphetamine Abuse
Vincent, B., & Shukla, M. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230907151226 · Cited by 13
The Growing Role of Cognitive Behavior Therapy in the Treatment of Parkinson’s Disease
Lopes, S. R., Khan, S., & Chand, S. P. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211018274 · Cited by 14
The Protein-Rich Fraction from Spirulina platensis Exerts Neuroprotection in Hemiparkinsonian Rats by Decreasing Brain Inflammatory-Related Enzymes and Glial Fibrillary Acidic Protein Expressions
Lopes, M. J. P., Delmondes, G. D. A., de Lacerda, G. M., Cavalcante, D. R. A., de Aquino, P. É. A., Lima, F. A. V., Neves, K. R. T., Costa, A. S., de Oliveira, H. D., Felipe, C. F. B., et al. (2022) · Journal of Medicinal Food · doi:10.1089/jmf.2021.0100 · Cited by 12
Affective Disorder and Functional Status as well as Selected Sociodemographic Characteristics in Patients with Multiple Sclerosis, Parkinson’s Disease and History of Stroke
Knapik, A., Krzystanek, E., Szefler–Derela, J., Siuda, J. S., Rottermund, J., Plinta, R., & Brzęk, A. (2020) · Medicina · doi:10.3390/medicina56030117 · Cited by 11
Rat models of major neurodegenerative disorders
Novati, A., Singer, E., Yu-Taeger, L., Clemensson, E. K. H., & Nguyen, H. P. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.19 · Cited by 10
Hyperbaric oxygen treatment for Parkinson's disease with severe depression and anxiety
Jinjin, X., Yang, S.-T., Sha, Y., Ge, Y.-Y., & Wang, J.-M. (2018) · Medicine · doi:10.1097/md.0000000000010029 · Cited by 11
Psychiatric predictors of quality of life in Parkinson's disease: A three-year longitudinal study
Dalrymple, W. A., Trach, S. K., Flanigan, J. L., Patrie, J. T., Henry, K. A., Harrison, M. B., Barrett, M. J., Figari‐Jordan, R., Shah, B., & Rossetti, M. A. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123248 · Cited by 10
Osteoarthritis Increases Paresthestic and Akathisic Pain, Anxiety Case-ness, and Depression Severity in Patients With Parkinson's Disease
Rana, A. Q., Qureshi, A. R., Akhter, S., Ingar, Y., Ali, A., Abdullah, I. Y., Madhosh, O., Sarfraz, Z., Rana, M. B., & Rana, R. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00409 · Cited by 10
The association between clinically relevant anxiety and other non-motor symptoms in Parkinson’s disease
Jiang, S., Yuan, Y., Tong, Q., Zhang, L., Xu, Q., Ding, J., & Zhang, K. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2320-0 · Cited by 10
Evaluating amino acids as protectants against β-N-methylamino-l-alanine-induced developmental neurotoxicity in a rat model
van Onselen, R., Scott, L. L., & Downing, T. G. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115140 · Cited by 10
Isolation Related to the COVID-19 Pandemic in People Suffering from Parkinson’s Disease and Activity, Self-Assessment of Physical Fitness and the Level of Affective Disorders
Knapik, A., Szefler–Derela, J., Wasiuk-Zowada, D., Siuda, J. S., Krzystanek, E., & Brzęk, A. (2021) · Healthcare · doi:10.3390/healthcare9111562 · Cited by 10
Tailoring anxiety assessment for Parkinson's disease: The Chinese Parkinson anxiety scale with cultural and situational anxiety considerations
Poon, S.-F., Tan, C., Hong, W., Chen, K. C., & Yu, R. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118284 · Cited by 9
Anxiety after subarachnoid hemorrhage: A systematic review and meta-analysis
Tang, W. K., Wang, L., Tsoi, K. K. F., Kim, J. M., Lee, S., & Kim, J. S. (2020) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2020.100060 · Cited by 10
Sexual Dysfunction and Related Factors in Patients With Parkinson's Disease
Haktanır, D., & Yılmaz, S. (2022) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20220907-02 · Cited by 9
Effectiveness and safety of herbal medicine Ukgansan for clinical symptoms in Parkinson's disease: A pilot, randomized, assessor-blinded clinical trial
Jin, C., Cho, K., Kwon, S., Lee, H., Kim, T., Jung, W., Moon, S., Cho, S., Kang, B.-K., Park, J., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1025269 · Cited by 8
Spectrum of Non-Motor Symptoms in Parkinson’s Disease — a Review
Rizvi, S. Z. H., Palimar, V., Gupta, C., & Andrade, L. S. (2024) · Annals of Clinical and Experimental Neurology · doi:10.17816/acen.1001 · Cited by 8
Physical activity as a mediator of anxiety and cognitive functioning in Parkinson's disease
Jones, J. D., Timblin, H., Rahmani, E., Garrett, S., Bunch, J., Beaver, H., & Hill, C. R. (2021) · Mental health and physical activity · doi:10.1016/j.mhpa.2021.100382 · Cited by 8
Age-Dependent Neuropsychiatric Symptoms in the NF-κB/c-Rel Knockout Mouse Model of Parkinson’s Disease
Parrella, E., Gallo, F. D., Porrini, V., Gussago, C., Benarese, M., Fabene, P. F., & Pizzi, M. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.831664 · Cited by 8
Neuroprotective Effect of Natural Indole and β-carboline Alkaloids against Parkinson’s Disease: An Overview
Shome, A., Chahat, Chawla, V., & Chawla, P. A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230913100624 · Cited by 8
The Relationship Between Social Anxiety Disorder and Motor Symptoms of Parkinson Disease: A Pilot Study
Moguel‐Cobos, G., Saldivar, C., Goslar, P. W., & Shill, H. A. (2020) · Psychosomatics · doi:10.1016/j.psym.2020.03.006 · Cited by 8
Towards a better Comprehension and Management of Pain and Psychological Distress in Parkinson’s: The Role of Catastrophizing
Zimmers, S., Robieux, L., & Bungener, C. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887231154932 · Cited by 9
Impact of Physiotherapy Absence in COVID-19 Pandemic on Neurological State of Patients With Parkinson Disease
Kapel, A., Serdoner, D., Fabiani, E., & Velnar, T. (2021) · Topics in Geriatric Rehabilitation · doi:10.1097/tgr.0000000000000304 · Cited by 8
Ideal animal models according to multifaceted mechanisms and peculiarities in neurological disorders: present and challenges
Lamichhane, S., Seo, J., Jeong, J. H., Lee, S., & Lee, S. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01527-9 · Cited by 8
Ferroplasticity drives social isolation-induced anxiety via a ventral hippocampal iron-α-synuclein axis
Wang, Z., Yang, S., Huang, T., Zhao, J., Tan, S., Zhang, Y., Lǚ, T., Qiu, P., Min, J., & Wang, F. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.12.022 · Cited by 7
ON-OFF Effects of Dopaminergic Therapy on Psychiatric Symptoms in Parkinson’s Disease
Ganjavi, H., & MacDonald, P. A. (2014) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.14030055 · Cited by 9
Clinical practice guidelines based on evidence for cognitive‐behavioural therapy in Parkinson's disease comorbidities: A literature review
Zečević, I. (2020) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2448 · Cited by 7
Managing Depression in Parkinson’s Patients: Risk Factors and Clinical Pearls
Biemiller, R. A., & Richard, I. H. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.31 · Cited by 6
Exploring Nonmotor Neuropsychiatric Manifestations of Parkinson Disease in a Comprehensive Care Setting
Dhingra, A., Janjua, A. U., Hack, L. M., Waserstein, G., Palanci, J. M., & Hermida, A. P. (2020) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988720915525 · Cited by 7
The effect of physical exercise on anxiety in people with parkinson’s disease: A systematic review of randomized control trials
Abuoaf, R., AlKaabi, R., Saleh, A. M., Zerough, U., Hartley, T., van Niekerk, S.-M., Khalil, H. W., & Morris, L. D. (2023) · Neurorehabilitation · doi:10.3233/nre-220264 · Cited by 6
A guide to management of neuropsychiatric manifestations of Parkinson’s disease
Ruiz, R. M. M., Evans, A. H., Velakoulis, D., & Looi, J. C. (2016) · Australasian Psychiatry · doi:10.1177/1039856216654394 · Cited by 6
Cognitive dysfunction and neuropsychiatric aspects of Parkinson's disease
Austgen, G., & Marsh, L. (2022) · Progress in brain research · doi:10.1016/bs.pbr.2022.01.009 · Cited by 6
Self-citation
Parkinson’s Disease: Basic Pathomechanisms and a Clinical Overview
Noyce, A. J., & Bandopadhyay, R. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_3 · Cited by 7
Impact of hypersexuality on spousal carers of patients with Parkinson’s disease and frontotemporal dementia: a qualitative study
Tayim, N., Panicker, J. N., Foley, J. A., Selai, C. E., & Sheikh, W. G. E. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-090870 · Cited by 5
Two-phase hybrid explainable machine learning model in the early diagnosis of motor and non-motor symptoms of Parkinson’s disease
Aggarwal, N., Saini, B. S., & Gupta, S. (2025) · Neurocomputing · doi:10.1016/j.neucom.2025.130004 · Cited by 5

Authors: Chen, J. J., & Marsh, L.
Affiliations: Loma Linda University (US)
Michael E. DeBakey VA Medical Center (US)
ORCID: Chen, Jack J.
Marsh, Laura
Venue: Therapeutic Advances in Neurological Disorders
Publisher: SAGE Publications
Published: 2013-07-17
Volume: 7
Issue: 1
Pages: 52-59
ISSN: 1756-2856 (ISSN-L)
1756-2864
DOI: 10.1177/1756285613495723
PMC: PMC3886380
OpenAlex: W2149341227
Cited by: 161
References: 69
Citations by year: 2026: 12 · 2025: 14 · 2024: 18 · 2023: 10 · 2022: 17 · 2021: 20 · 2020: 15 · 2019: 15 · 2018: 7 · 2017: 8 · 2016: 10 · 2015: 10 · 2014: 5
FWCI: 1.09
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Therapeutic Advances in Neurological Disorders (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords: Parkinson's disease, anxiety, psychiatric comorbidity, benzodiazepines, bromazepam, selective serotonin reuptake inhibitors, multimodal therapy, quality of life, caregiver burden, fall risk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anxiety in Parkinson's disease: identification and management

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks